An Fc-silenced immunoglobulin G1 (IgG1) bispecific monoclonal antibody against the tumor-associated antigen (TAA) CD30 (tumor necrosis factor receptor superfamily member 8; TNFRSF8) and T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD30/CD3 bispecific antibody GEN3017 targets and binds to both CD30 on the surface of tumor cells and CD3 on T-cells. This results in the cross-linking of tumor cells and T-cells, and induces a cytotoxic T-lymphocyte (CTL) response against CD30-expressing tumor cells. CD30, a member of the tumor necrosis factor receptor superfamily, is overexpressed on the surfaces of certain tumor cells.